Full Text View
Tabular View
No Study Results Posted
Related Studies
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
This study has been completed.
Study NCT00001477   Information provided by National Institutes of Health Clinical Center (CC)
First Received: November 3, 1999   Last Updated: March 3, 2008   History of Changes

November 3, 1999
March 3, 2008
August 1995
 
 
 
Complete list of historical versions of study NCT00001477 on ClinicalTrials.gov Archive Site
 
 
 
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy

Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.

Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.

 
Observational
 
  • Communicable Diseases
  • Opportunistic Infections
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
300
October 2000
 

Patients older than 18 years of age.

Ability to give informed consent.

No medical contraindication to phlebotomy.

Epidemiologically at risk for tuberculosis or for an opportunistic infection.

Patients who can identify a responsible health care provider as someone willing to provide clinical information and to receive medically important information.

Both
 
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00001477
 
950176, 95-I-0176
National Institute of Allergy and Infectious Diseases (NIAID)
 
 
National Institutes of Health Clinical Center (CC)
February 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP